Investigational Peptide Drugs: Diabetes & Obesity Review

Investigational Peptide Drugs: Diabetes & Obesity Review. 2019-2026 review of investigational peptide drugs for diabetes and obesity, including retatrutide, CagriSema, survodutide, mazdutide, and amylin analogs. Key Takeaways The 2019-2026 diabetes and obesity peptide pipeline is mostly incretin-based: GLP-1, GIP, glucagon, amylin, and related gut-hormone pathways dominate late-stage development. Retatrutide is the highest-profile investigational peptide drug: Eli Lilly's triple GIP/GLP-1/glucagon agonist is in Phase 3 programs for obesity, type 2 diabetes, and cardiometabolic outcomes. CagriSema expands the field beyond GLP-1 alone: Novo Nordisk's cagrilintide/semaglutide combination pairs an amylin analog with a GLP-1 receptor agonist. Survodutide and mazdutide are dual GLP-1/glucagon agonists: Both target obesity and metabolic disease, but their regulatory geography and development paths differ. Not every important candidate is a peptide: Oral small-molecule GLP-1 drugs like orforglipron compete in the same market but are not peptide drugs. Research status matters: Investigational peptides are not FDA-approved for personal use until regulators review safety, efficacy, manufacturing, and labeling data. This 2019-2026 review focuses on investigational peptide drugs for diabetes and obesity : the compounds still moving through clinical development, the receptor pathways they target, and how they differ from FDA-approved drugs like semaglutide and tirzepatide. For the full baseline of already approved diabetes peptide therapies, start with our peptides for diabetes treatment 2026 guide. This article narrows the lens to the pipeline: retatrutide, CagriSema, survodutide, mazdutide, amylin analogs, and other candidates that shaped the 2019-2026 research window. What Counts as an Investigational Peptide Drug? An investigational peptide drug is a peptide-based therapeutic candidate being studied under a formal development program but not yet approved for the target indication. In diabetes and obesity, that usually means a modified gut-hormone analog designed to last longer than the native hormone and activate one or more metabolic receptors. The distinction matters. Semaglutide and tirzepatide are peptide-based drugs, but they are no longer investigational for their approved indications. Retatrutide, CagriSema, survodutide, and several amylin or glucagon pathway candidates remain investigational in the United States for diabetes, obesity, or both as of May 2026. Why 2019-2026 Changed the Pipeline The 2019-2026 period began with a major milestone: oral semaglutide was approved for type 2 diabetes in 2019, proving that peptide therapeutics could move beyond injections when absorption technology worked. The bigger shift came after semaglutide and tirzepatide showed double-digit weight loss, turning incretin biology into the central drug-development platform for obesity and related metabolic disease. Recent reviews describe the field as an expanding set of single, dual, and triple receptor strategies built around GLP-1, GIP, glucagon, amylin, calcitonin-family receptors, and peptide YY pathways. The common goal is no longer glucose lowering alone. Sponsors are also testing weight loss, cardiovascular risk, kidney outcomes, liver disease, sleep apnea, and other obesity-related complications. The phrase "diabetes and obesity" is also important because these are no longer separate development tracks. Obesity trials now routinely measure glycemic status, prediabetes progression, waist circumference, blood pressure, lipids, kidney markers, liver-fat endpoints, and sleep apnea severity. Diabetes trials increasingly report body-weight reduction as a major secondary endpoint. That overlap is why the 2019-2026 review literature reads less like a diabetes-drug pipeline and more like a cardiometabolic disease pipeline. How to Read the 2019-2026 Review Literature Most review papers in this space organize the pipeline by receptor target rather than by brand name. That is the right way to read the field. The receptor strategy usually tells you what a candidate is trying to improve compared with older GLP-1 drugs. Single GLP-1 receptor agonists established the class: semaglutide, liraglutide, dulaglutide, exenatide, and related drugs reduce glucose, appetite, and body weight through one core incretin pathway. Dual agonists add GIP, glucagon, or amylin biology to broaden the metabolic effect. Triple agonists attempt to combine multiple signals in one molecule so the drug can affect appetite, insulin secretion, glucagon handling, liver metabolism, and energy expenditure at the same time. When a review article says an investigational peptide is "next generation," the claim usually comes from one of four places: broader receptor coverage, longer half-life, easier administration, better tolerability, or superior results on weight and HbA1c. A serious review should separate those claims. A drug can be mechanistically elegant and still fail because nausea, vomiting, discontinuation, manufacturing complexity, or cardiovascular uncertainty prevents approval. Receptor Strategies That Matter Most The peptide pipeline is crowded, but the important targets cluster into a few pathways. GLP-1 improves glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite. GIP may add insulinotropic effects and appears to work differently when paired with GLP-1 than it does alone. Glucagon receptor activation is more complicated: glucagon can raise glucose, but in engineered multi-agonists it may also increase energy expenditure, fat oxidation, and liver-metabolic effects when balanced against GLP-1 activity. Amylin is a separate satiety and post-meal glucose pathway. It is not just "another GLP-1." Amylin analogs slow gastric emptying, reduce food intake, and complement insulin biology. That is why CagriSema and cagrilintide matter: they represent a bet that adding amylin biology can produce stronger or more durable obesity results than simply escalating GLP-1 dose. The clinical question is not which receptor sounds best on paper. It is whether the final receptor balance produces enough benefit to justify side effects and long-term use. A triple agonist with impressive weight loss but poor tolerability may lose to a dual agonist that patients can stay on. A combination product may beat monotherapy on efficacy but face access, manufacturing, or payer hurdles. Those are the practical questions behind every 2019-2026 pipeline review. Retatrutide: Triple GIP, GLP-1, and Glucagon Agonism Retatrutide (LY3437943) is Eli Lilly's investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. It is the most visible investigational peptide drug in this category because it builds directly on tirzepatide's dual incretin model while adding glucagon receptor activity for additional energy-expenditure and liver-metabolic effects. ClinicalTrials.gov lists TRIUMPH-2 as a Phase 3 study of retatrutide in participants with type 2 diabetes who have obesity or overweight. Lilly is also running broader obesity and outcomes studies, including programs that enroll people with obesity-related kidney or cardiovascular risk. For the dedicated regulatory timeline, see our retatrutide approval status 2026 tracker. Retatrutide is especially important for diabetes-and-obesity search intent because it sits at the exact overlap of both markets. It is not merely an obesity drug being watched by diabetes patients, and it is not merely a glucose-lowering drug with weight loss as a side effect. Its Phase 3 program is designed around the reality that obesity, type 2 diabetes, kidney risk, sleep apnea, and cardiovascular disease often travel together. The key uncertainty is whether the triple-receptor profile can preserve enough tolerability at effective doses. For researchers reading the literature, the useful comparison is not just "retatrutide vs tirzepatide." It is retatrutide against the whole next-generation field: CagriSema vs retatrutide , survodutide's GLP-1/glucagon strategy, and future oral or combination approaches. CagriSema: Amylin Plus GLP-1 CagriSema combines cagrilintide, a long-acting amylin analog, with semaglutide, a GLP-1 receptor agonist. This is an important shift because it tests whether the next step after GLP-1 is not always another incretin receptor, but a second satiety pathway. ClinicalTrials.gov lists REDEFINE 2 as a Phase 3 study of cagrilintide/semaglutide in adults with overweight or obesity and type 2 diabetes. Other CagriSema studies compare the combination against active incretin comparators or evaluate long-term weight maintenance and cardiometabolic endpoints. CagriSema also matters because it tests a commercial and clinical question: can a combination of two known peptide mechanisms outperform a single highly engineered multi-agonist? If the answer is yes, the future of diabetes and obesity treatment may look more like fixed-dose peptide combinations. If the answer is no, single-molecule multi-agonists like retatrutide may keep the strategic advantage. From an SEO standpoint, CagriSema belongs in this article even though semaglutide itself is already approved. The investigational part is the combination strategy, the cagrilintide component, and the clinical question of whether amylin plus GLP-1 can become a next-generation obesity and diabetes platform. Survodutide: Dual GLP-1 and Glucagon Agonism Survodutide (BI 456906) is a dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. It is designed to pair GLP-1 appetite and glycemic effects with glucagon-linked energy expenditure and liver-metabolic activity. The SYNCHRONIZE program includes a Phase 3 trial in participants with overweight or obesity and type 2 diabetes. That makes survodutide one of the more direct retatrutide-adjacent candidates, even though it omits GIP receptor agonism and uses a dual rather than triple receptor profile. The GLP-1/glucagon design is attractive because it may address obesity and liver-metabolic disease together. The tradeoff is receptor balance. Too much glucagon activity could undermine glucose control, while too little may fail to add meaningful energy-expenditure benefit. The literature around survodutide is therefore useful for understanding how sponsors try to tune glucagon biology rather than simply avoid it. Mazdutide: Dual GLP-1 and Glucagon in China and Global Research Mazdutide is another dual GLP-1/glucagon receptor agonist, developed by Innovent Biologics with Lilly involvement. It has generated clinical data in both obesity and type 2 diabetes populations, especially in China, where regulatory development has moved faster than in the United States. For PeptideStack readers, the key SEO distinction is that mazdutide belongs in the diabetes and obesity investigational-drug conversation, but it should not be treated as an FDA-approved U.S. therapy. For a mechanism comparison against tirzepatide and retatrutide, see our mazdutide vs tirzepatide vs retatrutide breakdown. Mazdutide is also a reminder that the 2019-2026 pipeline is global. A candidate can be clinically advanced in one region while remaining investigational or commercially unavailable in another. Any review of investigational peptide drugs should specify geography, because "approved," "Phase 3," and "available" do not mean the same thing across the United States, China, Europe, and other markets. Amylin and Calcitonin-Family Peptide Strategies Amylin is co-secreted with insulin and helps regulate satiety, gastric emptying, and post-meal glucose dynamics. Pramlintide, an amylin analog, is already FDA-approved as an adjunct to mealtime insulin, but the obesity pipeline is focused on longer-acting and more tolerable amylin-family drugs. Recent amylin-receptor reviews highlight cagrilintide, ZP8396, amycretin, and dual amylin/calcitonin receptor agonists as strategies being explored for obesity and type 2 diabetes. These programs matter because they may complement GLP-1 therapy rather than simply trying to replace it. Amylin-family drugs may be especially useful where appetite regulation is the primary goal and glycemic control is already handled by GLP-1, GIP/GLP-1, insulin, or other therapies. They also create a different tolerability profile to watch. Because amylin slows gastric emptying and affects satiety, researchers still need to track nausea, discontinuation, and whether combination therapy increases or smooths gastrointestinal side effects compared with GLP-1 alone. Trial Endpoints That Separate Hype From Evidence For this keyword, the best content should not stop at naming pipeline drugs. It should explain which trial endpoints matter. In type 2 diabetes, HbA1c reduction remains central, but it is no longer the only meaningful measure. Weight loss, fasting glucose, time in range, insulin sensitivity, blood pressure, lipid changes, kidney markers, liver-fat measures, and adverse-event discontinuation rates all shape how a candidate is judged. In obesity trials, percent body-weight change is the headline endpoint, but it can be misleading without context. Researchers should look at baseline BMI, diabetes status, dose escalation, length of follow-up, plateau timing, regain after discontinuation, lean-mass preservation, and whether participants had obesity-related complications at entry. A 15% weight-loss result in a diabetes population may not be directly comparable to a 20% result in a non-diabetes obesity trial. Safety endpoints are just as important. The class-wide questions include nausea, vomiting, diarrhea, gallbladder events, pancreatitis signals, heart-rate changes, hypoglycemia risk when combined with insulin or sulfonylureas, and discontinuation due to adverse events. The strongest candidates will need durable benefits without intolerable side effects over long follow-up periods. Pipeline Comparison Table Candidate Receptor Strategy Main Sponsor 2026 U.S. Status Core Intent Retatrutide GIP / GLP-1 / glucagon triple agonist Eli Lilly Phase 3, investigational Obesity, T2D, cardiometabolic outcomes CagriSema Amylin analog + GLP-1 agonist Novo Nordisk Phase 3, investigational combination Obesity and T2D weight management Survodutide GLP-1 / glucagon dual agonist Boehringer Ingelheim / Zealand Pharma Phase 3, investigational Obesity, T2D, liver-metabolic disease Mazdutide GLP-1 / glucagon dual agonist Innovent / Lilly Not FDA-approved; global development varies Obesity and type 2 diabetes Cagrilintide Long-acting amylin analog Novo Nordisk Investigational Satiety and weight management Amycretin Amylin / GLP-1 receptor activity Novo Nordisk Investigational Obesity and metabolic disease Approved vs Investigational Peptide Drugs Approved peptide drugs have FDA-reviewed labeling, manufacturing controls, dosing instructions, contraindications, and safety monitoring requirements. Investigational peptide drugs do not. They may have promising Phase 2 or Phase 3 data, but they remain research-stage until a regulator approves a specific product for a specific indication. This is why retatrutide and CagriSema should not be described as available diabetes or obesity therapies in 2026. They are clinical-trial candidates. Tirzepatide and semaglutide, by contrast, have approved brands and labels for diabetes and/or chronic weight management. For the broader approved-drug landscape, see our therapeutic peptides list 2026 . Peptide Drugs vs Adjacent Non-Peptide Competitors One reason the search landscape gets messy is that the obesity and diabetes pipeline includes both peptide drugs and non-peptide incretin competitors. Oral semaglutide is a peptide formulation. Retatrutide, tirzepatide, cagrilintide, survodutide, and mazdutide are peptide or peptide-like therapeutic designs. But some oral GLP-1 candidates are small molecules, not peptides. That distinction matters for an article targeting investigational peptide drugs. Small-molecule GLP-1 drugs may compete commercially with peptide injections, and they may appear in the same reviews, but they should not be counted as peptide therapeutics unless the molecule itself is peptide-based. The best pipeline pages explain the competitive context without blurring the chemistry. Administration route is another important difference. Injectable peptides often achieve long half-lives through fatty-acid acylation, Fc fusion, albumin binding, or other modifications. Oral peptide delivery requires absorption enhancers or formulation tricks because peptides are vulnerable to gastrointestinal degradation. Small molecules avoid some of those delivery problems, but they may face different selectivity, potency, and safety challenges. What the 2019-2026 Reviews Agree On Across recent reviews, the same themes appear repeatedly: GLP-1 therapy proved the platform, dual and triple agonists aim for stronger weight and metabolic effects, and amylin-based combinations may provide a second major path beyond incretin escalation. The unresolved questions are long-term tolerability, muscle and lean-mass preservation, discontinuation effects, cardiovascular and kidney outcomes, and access. That makes the keyword phrase "investigational peptide drugs for diabetes and obesity reviews 2019-2026" unusually literal. Searchers are looking for a synthesis of the review literature, not a single product page. The winning page should explain the whole pipeline and separate peptide drugs from adjacent non-peptide oral incretin candidates. The reviews also agree that the field is moving from simple efficacy comparisons toward durability and disease-modification questions. Can these drugs prevent progression from prediabetes to type 2 diabetes? Can they reduce kidney or cardiovascular events? Can they improve metabolic dysfunction-associated steatotic liver disease? Can patients maintain weight loss after dose reduction or discontinuation? Those questions will determine whether the next generation becomes a temporary weight-loss tool or a chronic cardiometabolic platform. Another shared theme is that better efficacy can make trial interpretation harder. When approved comparators like tirzepatide and semaglutide are already powerful, placebo-controlled results are no longer enough to define leadership. The most useful future trials will compare investigational peptides against active standards of care, report discontinuation carefully, and separate diabetes populations from non-diabetes obesity populations. Research Evidence and Trial Sources The strongest evidence base comes from ClinicalTrials.gov trial records, peer-reviewed review articles in journals such as Metabolism , Peptides , and Nature Reviews Drug Discovery , plus sponsor-published Phase 3 readouts that still require peer-reviewed confirmation. This article prioritizes the formal trial and review record over forum discussion or vendor claims. Source Type What It Confirms How to Use It ClinicalTrials.gov Trial phase, population, sponsor, status, endpoints Best source for whether a candidate is actually in human testing Peer-reviewed reviews Mechanism, pathway rationale, class-level trends Best source for comparing GLP-1, GIP, glucagon, and amylin strategies FDA labels and approval databases Approved indications and official safety language Best source for separating approved from investigational status Sponsor releases Topline data before journal publication Useful but should be treated as preliminary until peer reviewed Frequently Asked Questions What are the main investigational peptide drugs for diabetes and obesity in 2026? The main investigational peptide drugs include retatrutide, CagriSema, survodutide, mazdutide, cagrilintide, amycretin, and other amylin or multi-agonist candidates. Retatrutide, CagriSema, and survodutide are especially important because they are in large Phase 3 programs. Is retatrutide FDA-approved for diabetes or obesity? No. Retatrutide remains investigational as of May 2026. It is in Phase 3 studies for obesity, type 2 diabetes with overweight or obesity, and broader cardiometabolic outcomes, but it does not have FDA approval for personal use. Is CagriSema a peptide drug? Yes. CagriSema combines two peptide-based therapies: cagrilintide, an amylin analog, and semaglutide, a GLP-1 receptor agonist. The combination is investigational for obesity and diabetes-related weight management in the United States. Are oral GLP-1 pipeline drugs peptides? Not always. Oral semaglutide is a peptide drug, but several newer oral GLP-1 candidates are small molecules rather than peptides. They compete in the same diabetes and obesity market, but they are not investigational peptide drugs in the strict biochemical sense. Which investigational peptide is closest to approval? That depends on the indication and trial readouts. As of 2026, late-stage programs such as CagriSema, retatrutide, and survodutide are the most important to watch, but FDA approval requires a complete application, regulator review, manufacturing assessment, and final labeling decision. Can research peptides be used instead of approved diabetes or obesity medications? No. Investigational peptides discussed in this article are not substitutes for FDA-approved medications or physician-supervised care. Compounds sold as research peptides are intended for laboratory research only and should not be used as human treatments. Bottom Line The 2019-2026 diabetes and obesity peptide pipeline is no longer just "more GLP-1." It is a multi-pathway race across triple agonists, amylin combinations, dual GLP-1/glucagon drugs, and longer-acting metabolic peptide designs. The commercial winners are still unknown, but the scientific direction is clear: future peptide drugs will target multiple appetite, glucose, liver, and energy-expenditure pathways at once. References ClinicalTrials.gov. Retatrutide TRIUMPH-2: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight. NCT05929079 ClinicalTrials.gov. CagriSema REDEFINE 2: Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. NCT05394519 ClinicalTrials.gov. Survodutide SYNCHRONIZE-2: BI 456906 in participants with overweight or obesity and type 2 diabetes. NCT06066528 Muzurovic E, Katsiki N, Volcansek S, et al. Emerging incretin- and multi-agonist-based treatments. Metabolism . 2026;177:156494. doi:10.1016/j.metabol.2026.156494 Drucker DJ. Advances in oral peptide therapeutics. Nature Reviews Drug Discovery . 2020;19:277-289. Nature Reviews Drug Discovery ClinicalTrials.gov. CagriSema versus tirzepatide in people with type 2 diabetes. NCT06534411 Disclaimer: This article discusses investigational compounds and clinical research for educational purposes only. It is not medical advice, does not recommend any unapproved drug, and does not provide dosing or treatment guidance. PeptideStack does not provide medical diagnosis or treatment recommendations. PeptideStack page context: visitors can use the header navigation to reach the product catalog, blog, calculators, supplier pages, discount-code pages, contact page, legal policies, shipping policy, refund policy, privacy policy, terms, and research disclaimer. The site is organized around research peptide education, supplier transparency, product comparison, vendor review content, discount-code tracking, and calculator tools for reconstitution or unit conversion research planning. PeptideStack separates research-use-only peptide information from FDA-approved medication and licensed telehealth pathways. Research peptide pages are informational and are not medical advice, prescription guidance, dosing instructions, treatment recommendations, or instructions for human consumption. Many pages include affiliate disclosures because PeptideStack may earn a commission when visitors click external supplier or telehealth links. That commission does not change the price paid by visitors and does not mean PeptideStack manufactures, sells, distributes, compounds, or ships peptides or medications. Supplier and product pages should be evaluated for third-party testing, batch-specific certificates of analysis, named laboratory verification, transparent pricing, realistic delivery expectations, payment security, refund policies, support quality, and consistent research-use-only labeling. Blog pages connect related guides, comparison articles, FDA approval status explainers, safety context, legality resources, product pages, vendor reviews, and calculator tools so visitors can keep researching without relying on a single supplier claim. Calculator pages are educational tools for laboratory planning and should be cross-checked against professional protocols, institutional requirements, and applicable laws. Legal and disclaimer pages explain the boundaries of PeptideStack content and the responsibility of visitors who evaluate third-party vendors. The rendered interface may add interactive details such as mobile navigation labels, product tabs, share buttons, related article cards, disclosure boxes, call-to-action buttons, vendor selectors, copy-code controls, email-code forms, footer navigation, and status labels. The static HTML fallback includes this context so the same page purpose is understandable before the JavaScript application finishes loading. Visitors should treat PeptideStack as a research and comparison starting point. Final supplier evaluation should include direct review of the external vendor website, current product availability, checkout terms, applicable laws, institutional requirements, and any third-party laboratory documentation available for the exact product or batch being considered. Footer resources repeat important sitewide context: PeptideStack is independent, affiliate-supported, research-focused, and not a pharmacy or manufacturer. Pages may include links to the iOS app, calculators, blog hubs, product hubs, supplier comparisons, support contact, and policy documents. This repeated context is intentionally available in the raw HTML for crawlers that inspect a page before executing the React bundle. Raw HTML also includes page summaries for mobile crawlers using JavaScript rendering, desktop crawlers comparing source to rendered output, accessibility tools, and no-script visitors. The fallback is replaced by the React app in normal browsers but keeps the source document aligned with the visible page topic. This fallback keeps source HTML and rendered HTML closer for crawl diagnostics and SEO audits across crawled pages, routes, reports, and recrawls.